Want to join the conversation?
$BMY said CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naive Patients with Advanced Non-Small Cell Lung Cancer, failed to meet the primary endpoint of progression-free survival. The company will complete a full evaluation of the CheckMate -026 data and work with investigators on the future presentation of the results.
You are such a letdown $FII. I regret not selling you when you were nearing $33. Now I am stuck with you, you are stuck with me!
Can you imagine a food store with no cash registers? Well, it is coming true soon thanks to $AMZN. The company is opening its new grocery store in Seattle and it has no cash registers. AI takes over!